Chlamydia Infection Treatment Market Share, Size, Demands, Key Company Analysis and Industry Outlook 2027
According to MRFR analysis, the global chlamydia infection treatment market is expected to register a CAGR of~10% from 2021 to 2027and hold a value of USD 12,821.5 million till 2027. According to the Centers for Disease Control and Prevention (CDC), the chlamydial infection has the highest prevalence in people aged ≤24 years in the US. Moreover, asymptomatic infection is also very common among people. Therefore, annual screening of all sexually active women aged <25 years and older women at increased risk of infection is recommended.
Many market players are dominating the global chlamydia infection treatment market share. The prominent players are involved in strategic agreements, product launches, and joint ventures to sustain their market positions. For instance, in 2019, Statens Serum Institute, completed clinical phase 1 trial for a first-generation vaccine candidate (CTH522), based on the major outer membrane protein of the C trachomatis bacterium. The vaccine will provide a promising preventive therapy for chlamydia infection.
Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/10589
Segmentation
The global chlamydia infection treatment market growth has been segmented into causative organisms, route of administration, and distribution channel.
By Causative Organisms
- Chlamydia trachomatis
- Chlamydia pneumoniae
By Route of Administration
- Oral
- Injectable
- Others
By Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
Key Players
Some of the key players in the global chlamydia infection treatment market are
- Merck & Co. Inc. (US)
- Pfizer Inc (US)
- GlaxoSmithKline Plc (UK)
- AstraZeneca (UK)
- Gilead Sciences Inc.(US)
- Sanofi (France)
- Teva Pharmaceuticals (Israel)
- Sun Pharma (India)
- Eli Lilly and Company (US)
- Novartis (Switzerland)
- Others
Regional Analysis
By region, North America is anticipated to dominate the global chlamydia infection treatment market, owing to the well-established healthcare system, the high adoption rate in medical screening, and the presence of a high number of pharmaceutical and biopharmaceutical companies. Moreover, the high prevalence of STDs and rising government initiatives to spread awareness for STDs also drive the growth of the market.
On the other hand, the European chlamydia infection treatment market is driven by the rising R&D expenditure by biopharmaceutical companies, increasing investments in the R&D sector, and the presence of key market players.
Asia-Pacific is anticipated to be the fastest-growing region over the assessment period due to rapidly improving healthcare infrastructure, the rising pool of chlamydia-infected patients, wide adoption of STD screening, and the rapidly developing pharma and biopharma sector in the region.
Get Access Full Report @ https://www.marketresearchfuture.com/reports/chlamydia-infection-treatment-market-10589
Furthermore, the growth of the market in the rest of the world is attributed to the rising per capita expenditure of the population in the healthcare sector and the increasing adoption rate of medical screening in the region.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future (MRFR) team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian